The Tough Tech problem we are solving
The lymphatic system plays a critical role in regulating immune responses to cancer and serves as the primary means of metastasis in over 90% of cancer cases, yet lymphatic fluid remains largely inaccessible for routine diagnosis, monitoring, or research. Unlike blood, lymph is not easily sampled, creating a blind spot in understanding tumor progression, immune dynamics, and early metastatic spread, limiting the development of targeted therapies and personalized cancer care.
About our solution
Droplet Biosciences has pioneered the first lymph liquid biopsy platform, harnessing lymphatic fluid's powerful insights to transform cancer care. By harvesting and profiling patient lymph from routine surgical drain fluid—a simple, non-invasive byproduct post-operation—our technology unlocks real-time data on immune activity, circulating tumor cells, and metastatic potential. This approach delivers unprecedented precision for earlier detection, treatment response tracking, and breakthrough discoveries in oncology.